Coronavirus impact: 14 July - plenty of updates and a bizarre response from Manolete
Plenty of results and updates today, including a robust response from Manolete Partners, an insolvency litigation financing firm, to an article which questioned its results and reporting.
Manolete: why bother responding!
Previous article Next article
DON'T MISS OUT!
Get top investment ideas to help safeguard and grow your wealth.
Invaluable insight from the exciting world of smaller companies.
REGISTER FREE
More on AdEPT Technology
Chain gains | Another takeover | Big dividend
News covered here includes a promising update from a lowly valued engineering group, another equity raise…
As frustrating as ever
News from AIM covered here, include results from one of AIM’s more elderly companies and one…
More on Anexo Group PLC
Settlement disappoints | FDA approvals encourage
Updates covered here include news of a cash settlement for an unloved legal services business, a…
Good value | End of the road? | Focus on cash collection
Results and updates covered here includes a positive update from a well-established sector leader, whose shares…
More on Bango
Another IPO from 2021 tumbles
Yet another highly valued retail play, which only joined AIM a year ago, has seen its…
Coronavirus impact: 14 July - plenty of updates and a bizarre response from Manolete
Plenty of results and updates today, including a robust response from Manolete Partners, an insolvency litigation financing firm,…
More on EMIS Group PLC
Data wars underpin AI Wars
AI is the acronym of the moment, but data and data wars will determine the AI…
Loads of cash and heaps of potential
This AIM listed connected healthcare group has delivered excellent results and the growing focus on data…
More on Fevertree Drinks PLC
Compelling value | AI appeal
Results from an unusual investing company highlight its compelling value, while elsewhere there was news of…
Fevertree Drinks: is the valuation justified?
Shares in the premium mixer group rose strongly as it reported in-line results and, more significantly,…
More on Manolete Partners PLC
Naked Wines: stripping shareholders bare
Results and updates covered here include yet more disappointment for shareholders of online wine retailer Naked…
Vaccine countdown update: 12 Nov - apparent value here and probably a few traps
Our coverage here includes several modestly valued companies whose shares should recover strongly when the world…
More on Zoo Digital
Lofty valuations | Stretched balance sheets
Results and updates covered in our free update here include several companies carrying lofty…
Updates covered here include news of more big share purchases from a founder and CEO of…
More Director buying to encourage
More Company Insights
Chain gains | Another takeover | Big dividend
As frustrating as ever
Focus on the cash flow
Shares take a bath
Settlement disappoints | FDA approvals encourage
Good value | End of the road? | Focus on cash collection
Focus on the cash flow
Better than expected
Another IPO from 2021 tumbles
Coronavirus impact: 14 July - plenty of updates and a bizarre response from Manolete
Coronavirus impact: 20 May - Boohoo founders spot an opportunity
Coronavirus impact:14 May - infection prevention is booming and we learn a new term
Data wars underpin AI Wars
Loads of cash and heaps of potential
Not the best, but hardly the worst either
This AIM survivor is selective with the facts
Compelling value | AI appeal
Fevertree Drinks: is the valuation justified?
Plenty to encourage | Bonkers Bargain Upgrades
Big sell-off brings Director buying!
Naked Wines: stripping shareholders bare
Vaccine countdown update: 12 Nov - apparent value here and probably a few traps
Vaccine countdown update: 10 Nov - positive results from some, cash flow concerns with others
Coronavirus impact: 14 July - plenty of updates and a bizarre response from Manolete
Lofty valuations | Stretched balance sheets
More Director buying to encourage
Sensyne gets its dosh | Valuations!
AIM’s global leader and a smaller alternative
More Company Insights
Settlement disappoints | FDA approvals encourage
AIM new arrivals and departures May 2023
A tale of two fund managers
